224452-66-8 Usage
Description
Antibacterial retapamulin is a derivative of the natural
product pleuromutilin and was developed by Glaxo and approved
in the US in 2007 for the treatment of skin infections. It has a unique mechanism of action, inhibiting bacterial
protein synthesis by inhibiting the larger subunit of the ribosome,
and thus has no cross resistance to other antibacterial
agents.
Pleuromutilin is a tricyclic diterpenoid that was first isolated in 1951 from the edible mushroom Pleurotus mutilus. The first semisynthetic analogs tiamulin and valnemulin, developed for veterinary use, have been shown to interact uniquely with bacterial ribosomes by high affinity binding to a site on the 50S subunit. Binding to this site interferes with ribosomal peptidyl transferase activity, blocks P-site interactions, and prevents the evolution of active 50S ribosomal subunits. Retapamulin, the first pleuromutilin approved for human use, behaves similarly to selectively inhibit bacterial protein synthesis. This novel mechanism of action has been implicated in the lack of in vitro target-specific cross-resistance with other classes of antibiotics.
Originator
GlaxoSmithKline (US)
Uses
Different sources of media describe the Uses of 224452-66-8 differently. You can refer to the following data:
1. Retapamulin is a topical antibiotic, which binds to both E. coli and S. aureus ribosomes with similar potencies with Kd of 3 nM
2. Retapamulin is a semi-synthetic pleuormutilin prepared by reacting pleuromutilin tosylate with tropine-3-thiol to give a more hydrophobic analogue with a tertiary amine. This enables formulation as a stable hydrochloride salt. Retapamulin is a broad spectrum antibiotic with no cross resistance to existing antibiotic classes, and is the first pleuromutilin approved for human use. Like all the pleuromutilins, retapamulin inhibits protein synthesis by binding to domain V of 23S rRNA.
3. A broad spectrum antibiotic with no cross resistance to existing classes
4. Retapamulin is a semi-synthetic pleuromutilin prepared by reacting pleuromutilin tosylate with tropine-3-thiol to give a more hydrophobic analogue with a tertiary amine. This enables formulation as a stable hydrochloride salt. Retapamulin is a broad spectrum antibiotic with no cross resistance to existing antibiotic classes, and is the first pleuromutilin approved for human use. Like all the pleuromutilins, retapamulin inhibits protein synthesis by binding to domain V of 23S rRNA.
Brand name
Altabax
Pharmaceutical Applications
A semisynthetic pleuromutilin formulated as a 1% ointment
for topical use. It is active against staphylococci
(MIC 0.12 mg/L), including methicillin-resistant strains, and
against streptococci (MIC 0.03–0.25 mg/L), including Str.
pyogenes and Str. pneumoniae. Most enterococci and Gramnegative
bacilli are resistant. Propionibacteria are susceptible,
suggesting that it might be useful in acne. Early indications
suggest that resistance does not emerge readily, but experience
with veterinary pleuromutilins indicates that chromosomal
resistance may develop with extended use.
It is metabolized in the liver and rapidly excreted, precluding
use in systemic infection. Systemic exposure is said to be
low following topical application and it appears safe, but there
are few data on absorption through broken and unbroken skin.
Principal side effects noted include local irritation and occasional
allergic reactions. Licensed use is presently restricted to
the treatment of impetigo and uncomplicated skin infections.
Possible value in methicillin-resistant Staph. aureus (MRSA)
infection or carriage has not yet been established.
Side effects
The most frequent adverse event was application site irritation, but other side effects, occurring in o2% of patients, included headache, diarrhea, nausea, and nasopharyngitis. While there are no contraindications, it is recommended that pregnant women only use retapamulin when the potential benefits outweigh the potential risks since animal reproductive studies are not always predictive of human response. Likewise, nursing mothers are cautioned about the unknown possibility of retapamulin excretion in breast milk.
Synthesis
The synthesis of retapamulin begins with generation of the mesylate of pleuromutilin, isolated through fermentation of Clitopilus passeckerianus, followed by nucleophilic substitution with exo-8-methyl-8-azabicyclo[3.2.1]octan-3-thiol under basic conditions Shridhar Hegde and Michelle Schmidt (potassium-tert-butoxide in ethanol or tetrabutylammonium hydrogen sulfate in dichloromethane/water and sodium hydroxide at pH 12.5). The azabicyclic thiol derivative may be prepared via a Mitsunobu reaction between tropine and thioacetic acid.
references
[1] jones r n, fritsche t r, sader h s, et al. activity of retapamulin (sb-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. antimicrobial agents and chemotherapy, 2006, 50(7): 2583-2586.[2] rittenhouse s, biswas s, broskey j, et al. selection of retapamulin, a novel pleuromutilin for topical use. antimicrobial agents and chemotherapy, 2006, 50(11): 3882-3885.
Check Digit Verification of cas no
The CAS Registry Mumber 224452-66-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,4,4,5 and 2 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 224452-66:
(8*2)+(7*2)+(6*4)+(5*4)+(4*5)+(3*2)+(2*6)+(1*6)=118
118 % 10 = 8
So 224452-66-8 is a valid CAS Registry Number.
InChI:InChI=1/C30H47NO4S/c1-7-28(4)16-22(24(27(34)35)36-21-14-19-8-9-20(15-21)31(19)6)29(5)17(2)10-12-30(18(3)26(28)33)13-11-23(32)25(29)30/h7,17-22,24-26,33H,1,8-16H2,2-6H3,(H,34,35)/p-1/t17-,18+,19-,20+,21+,22+,24?,25+,26+,28-,29+,30+/m1/s1
224452-66-8Relevant articles and documents
Novel method for preparing retapamulin
-
, (2017/10/22)
The invention provides a novel method for preparing an externally applied antibacterial medicine retapamulin. According to the method, tiamulin is used as an initial raw material, and is subjected to five steps of physical chemical reactions and a purifying process to prepare the retapamulin; the initial raw material has controllable quality, and is suitable for new medicine research, development and application; and the method is simple in operation, controllable in condition, low in preparation cost and convenient for industrial production, and is a great innovation for the retapamulin synthesis method.
A Swedish he Moline synthesis method
-
, (2017/07/11)
The present invention provides a synthesis method for Retapamulin. The method comprises: using pleuromutilin as a starting material of one segment; obtaining PLM-TS by condensation reaction between the starting material and toluenesulfonyl chloride; using tropenol as a raw material of the other segment; obtaining TRP-MS by reaction between the raw material and toluenesulfonyl chloride; after performing substitution reaction between TRP-MS that uses water as a solvent and potassium ethyl xanthate, performing acidification between the substance and sulfuric acid to obtain an intermediate TRP-XAN; TRP-XAN undergoing hydrolysis in an ethanol NaOH solution; performing acidification between the substance and sulfuric acid to obtain an intermediate TRP-THI; the two segments TRP-THI and PLM-TS undergoing condensation reaction under alkaline conditions to obtain the final product, Retapamulin. The synthesis method for Retapamulin provided by the present invention is simple, environmentally friendly, easy in controlling the quality of intermediates of all steps, and suitable for the Retapamulin synthesis process in industrialized production.
